Tripathy Discusses the Use of HER2-Positive Breast Cancer Agents Across Other Cancer Types
July 22nd 2021Debu Tripathy, MD, discusses the use of tucatinib, capecitabine, and trastuzumab for the treatment of patients with HER2-positive breast cancer and leptomeningeal disease in other HER2-positive cancer types.
Watch
Ruxolitinib and the REACH Trials
July 21st 2021Key opinion leader, Yi-Bin Chen, MD, summarizes the clinical trial data supporting the recent FDA approval of ruxolitinib for the treatment of steroid-refractory acute GVHD and provides insights on a potential future role for ruxolitinib in steroid-refractory chronic GVHD.
Watch